Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec Inc's PLEGRIDY (Peginterferon beta-1a) approved in European Union for treatment of multiple sclerosis


Wednesday, 23 Jul 2014 11:41am EDT 

Biogen Idec Inc:Says European Commission (EC) has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a) as treatment for adults with relapsing-remitting multiple sclerosis (RRMS), most common form of multiple sclerosis (MS).PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe.PLEGRIDY, only pegylated interferon approved for use in RRMS, has been proven to significantly reduce important measures of disease activity, including number of relapses, MRI brain lesions, and disability progression.EC approval of PLEGRIDY is based on results from one of the largest pivotal studies of a beta interferon conducted, ADVANCE1, which involved more than 1,500 patients with relapsing forms of MS. 

Company Quote

342.4
1.515 +0.44%
26 Dec 2014